(Asp37)-Amyloid β-Protein (1-42) is the G37D mutant of wild-type Amyloid-beta (1-42) peptide [1] .

(D-Arg1,D-Pro2,D-Phe7,D-His9)-Substance P is a selective NK 1 receptor antagonist [1] .

(D-Arg1,D-Pro2,D-Phe7,D-His9)-Substance P is a selective NK 1 receptor antagonist [1] .

(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P is a neuropeptide Substance P antagonist [1] .

(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P is a neuropeptide Substance P antagonist [1] .

(D-Asp1)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer’s disease [1] .

(D-Asp1)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer’s disease [1] .

(D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) is a CRF antagonist. (D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) prevents the IL-1a induced Luteinizing hormone (LH) inhibition [1] .

(D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) is a CRF antagonist. (D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) prevents the IL-1a induced Luteinizing hormone (LH) inhibition [1] .

(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analog with K d s of 0.61, 11.05, 23.5, 1200 and >1000 nM for SSTR5 , SSTR3 , SSTR2 , SSTR1 and SSTR4 , respectively [1] .

(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analog with K d s of 0.61, 11.05, 23.5, 1200 and >1000 nM for SSTR5 , SSTR3 , SSTR2 , SSTR1 and SSTR4 , respectively [1] .

(D-Phe6,Leu-NHEt13,des-Met14)-Bombesin (6-14) is a bombesin ( BBN ) antagonist and can be used for the research of cancer [1] .

(D-Phe6,Leu-NHEt13,des-Met14)-Bombesin (6-14) is a bombesin ( BBN ) antagonist and can be used for the research of cancer [1] .

(D-Phe7)-α-MSH is an α-MSH analogue [1] .

(D-Phe7)-α-MSH is an α-MSH analogue [1] .

(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B is a competitive antagonist of Neurokinin B ( Neurokinin Receptor ) with a pA2 of 5.5. (D-Pro2,D-Trp6,8,Nle10)-Neurokinin B shows no influence on Substance P or Neurokinin A [1] .

(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B is a competitive antagonist of Neurokinin B ( Neurokinin Receptor ) with a pA2 of 5.5. (D-Pro2,D-Trp6,8,Nle10)-Neurokinin B shows no influence on Substance P or Neurokinin A [1] .

(D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] .

(D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] .

(D-Ser2)-Leu-Enkephalin-Thr is a delta selective agent of opioid receptor and shows analgesic effects.

(D-Ser2)-Leu-Enkephalin-Thr is a delta selective agent of opioid receptor and shows analgesic effects.

(D-Ser2)-Leu-Enkephalin-Thr is a delta selective agent of opioid receptor and shows analgesic effects.

(D-Ser2)-Leu-Enkephalin-Thr is a delta selective agent of opioid receptor and shows analgesic effects.

(D-Ser2)-Leu-Enkephalin-Thr is a delta selective agent of opioid receptor and shows analgesic effects.

(D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] .

(D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] .

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) acetate is a highly potent antagonist of parathyroid hormone (PTH) The Ki value is 69 nM in bovine renal cortical membrane.

(D-Trp6)-LHRH free acid is a luteinizing hormone-releasing hormone ( LHRH ) agonist [1] .

(D-Trp6)-LHRH free acid is a luteinizing hormone-releasing hormone ( LHRH ) agonist [1] .

(D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] .

(D-Tyr5,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] .

Selective vasopressin V1A receptor antagonist. Inhibits vasopressin and oxytocin-induced increases in intracellular calcium concentrations in vitro (IC50 values are 5 and 30 nM respectively). Exhibits potent and prolonged antivasopressor activity and induces anxiolytic-like effects in the dorsal, but not ventral, hippocampus in vivo.

(d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, an oxytocin receptor antagonist, abolishes oxytocin-enhanced inhibitory postsynaptic currents in CA1 pyramidal neurons [1] .